OMER: Summary for Omeros Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:46am EST - Canadian Markets open in 2 hours and 44 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Omeros Corporation (OMER)

On Feb 9: 5.69 USD 0.00 (0.00%)

MORE ON OMER

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Omeros Corporation (NGM:OMER) Delayed quote data

Last Trade:	5.69 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	5.69
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	13.50

Day's Range:	N/A - N/A
52wk Range:	5.27 - 9.49
Volume:	0
Avg Vol (3m):	45,754
Market Cap:	121.04M
P/E (ttm):	N/A
EPS (ttm):	-7.48
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m

Add OMER to Portfolio

Download Data

HEADLINES

•	Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
	PRNewswire (Thu, Jan 28)

•	After A Sluggish Year, VCs Eye Improvement
	Investor's Business Daily (Fri, Jan 8)

•	IPO comeback in 2009 sets stage for busy 2010
	AP (Thu, Dec 31)

•	The Worst IPOs Of 2009
	at Investopedia (Wed, Dec 16)

•	Worst IPOs of 2009: Biggest Stock Flops
	at TheStreet.com (Tue, Dec 15)

•	OMEROS CORP Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Wed, Dec 9)

•	Coverage initiated on Omeros by Needham
	Briefing.com (Tue, Dec 1)

•	New Star Analyst Rankings for Omeros Corporation
	StarMine (Sun, Nov 22)

•	OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition
	EDGAR Online (Thu, Nov 19)

•	Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
	PRNewswire (Thu, Nov 19)

More Headlines for OMER...

ANALYST

EPS Est (next year) (Dec-09) :	-1.43
EPS Est (in 2 years) (Dec-10) :	-1.44
Avg Rec (current)*:	1.6
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

Full Company Profile

Add to Portfolio

Email to a Friend

•